Loading clinical trials...
Loading clinical trials...
A Phase IIIb, Multi-center, Stratified, Open-Label Study to Evaluate the Immunogenicity, Steady State Trough Level, and Safety of Subcutaneous Abatacept (BMS-188667) in Subjects With Rheumatoid Arthritis Administered With or Without Background Methotrexate
To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Rheumatology Associates Of North Alabama
Huntsville, Alabama, United States
Coastal Clinical Research Inc
Mobile, Alabama, United States
Stanford University School Of Medicine
Palo Alto, California, United States
Boulder Medical Center
Boulder, Colorado, United States
The Arthritis Center
Palm Harbor, Florida, United States
Medical Towers South
Louisville, Kentucky, United States
Westroads Medical Group
Omaha, Nebraska, United States
Regional Rheumatology Associates
Binghamton, New York, United States
Physicians East, Pa
Greenville, North Carolina, United States
Healthcare Research Consultants
Tulsa, Oklahoma, United States
Start Date
December 1, 2007
Primary Completion Date
December 1, 2008
Completion Date
February 1, 2014
Last Updated
March 23, 2015
119
ACTUAL participants
abatacept
DRUG
Methotrexate (MTX)
DRUG
Lead Sponsor
Bristol-Myers Squibb
NCT07484243
NCT06647069
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions